SLC39A11 Antibody

Overview of SLC39A11 Antibody

The SLC39A11 antibody is a polyclonal rabbit-derived immunoglobulin (IgG) that binds specifically to epitopes of the SLC39A11 protein. It is available in various conjugated forms (e.g., HRP, Biotin) for diverse experimental applications. Key features include:

• Target: SLC39A11 (ZIP11), a transmembrane protein involved in zinc and manganese transport .

• Epitope Regions:

  • AA 93–193 (Biotin-conjugated)

  • AA 251–342 (HRP-conjugated)

  • AA 130–180 (unconjugated)

• Reactivity: Human, mouse, and rat .

Alzheimer’s Disease

• Upregulation in AD Brains: SLC39A11 protein levels are elevated in the inferior temporal cortex and frontal cortex of Alzheimer’s patients (Braak stages 4–6), compared to age-matched controls .

• Co-Localization with Pathological Markers:

  • Amyloid Plaques: SLC39A11 co-deposits with β-amyloid plaques in AD cerebral cortex .

  • Phosphorylated Tau: Co-localizes with AT100-positive neurofibrillary tangles .

  • Experimental Models: Overexpression in H4-neuroglioma cells (Swedish Mutant APP) confirms its role in neurodegenerative processes .

Aging and Longevity

• Manganese Transport: Recent studies identify SLC39A11 as a conserved manganese (Mn) transporter in zebrafish and mice. Global knockout mice exhibit subtle systemic Mn elevation, suggesting a regulatory role in Mn homeostasis .

• Cellular Senescence:

  • SLC39A11 Knockdown: Increases senescence in human fibroblasts (SA-β-Gal activity) .

  • Mn Exposure: Comparable senescence levels observed under high extracellular Mn, indicating Mn-dependent protective effects .

Diagnostic and Therapeutic Potential

• Diagnostic Biomarker: Quantitative PCR and Western blot using SLC39A11 antibodies enable detection of mRNA/protein dysregulation in AD and aging .

• Therapeutic Target: Antibodies or modulators targeting SLC39A11 may mitigate neurodegeneration by regulating metal ion homeostasis .